miransertib mesylate

Miransertib mesylate is a selective AKT inhibitor that binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may result in reduction in tumor cell proliferation and the induction of tumor cell apoptosis.

MeTC7 是一种维生素 D 受体 (VDR) 拮抗剂，具有抗肿瘤活性，抑制 PD-L1，可在体内抑制异种移植物和转基因肿瘤的生长。